ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Pulmonary Involvement"

  • Abstract Number: 2623 • 2013 ACR/ARHP Annual Meeting

    A CT Evaluation Of Pulmonary and Cardiac Lesions In BEHÇET’S Syndrome Patients Without Pulmonary Symptoms

    Emire Seyahi1, Deniz Cebi Olgun2, SerdaL Ugurlu1, Idil Hanci3, Reona Takahashi4 and Hasan Yazici1, 1Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 2Department of Radiology,, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 3Department of Neurology, Krankrenhaus Nordwest, Frankfurt am Main, Frankfurt, Germany, 4Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

    Background/Purpose:  In Behçet’s syndrome (BS) patients with symptomatic pulmonary artery involvement (PAI) varying and multiple pulmonary parenchymal and cardiac lesions can be seen in thorax CT…
  • Abstract Number: 619 • 2013 ACR/ARHP Annual Meeting

    Survival and Prognostic Factors In Patients With Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Results From Korean Nationwide Registry

    Kwi Young Kang1, Chan Hong Jeon2, Sung Jae Choi3, Seung-Ki Kwok4, Seong-Kyu Kim5, Hyoun-Ah Kim6, Eon Jeong Nam7, Yong-Beom Park8, Kichul Shin9, Jaejoon Lee10, Chang-Hoon Lee11, Chan-Bum Choi12, Shin-Seok Lee13 and Dae-Hyun Yoo14, 1Rheumatology, Internal Medicine, Catholic University of Korea, Incheon St. Mary's Hospital, Seoul, South Korea, 2Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, 3Rheumatology, Korea University Medical Center, Seoul, South Korea, 4Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, 5Catholic University of Daegu School of Medicine, Daegu, South Korea, 6Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, 7Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, 8Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 9Rheumatology, College of Medicine, Seoul National University, Seoul, South Korea, 10Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 11Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, 12Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, 14Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissue disease (CTD). We sought to quantify survival and determine factors predictive…
  • Abstract Number: 2610 • 2013 ACR/ARHP Annual Meeting

    A New Pathogenic Role Of BAFF As a Critical Mediator Of Skin and Lung Fibrosis In Experimental Bleomycin-Induced Pulmonary Fibrosis, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis

    Antoine Francois1, Pascal Schneider2, Anne Davidson3, Emmanuel Chatelus4, Jérôme Avouac5, Yannick Allanore6, Bérengère Villeret7, Aurélie Gombault7, Paméla Gasse8, Sylvain Marchand Adam9, Bernhard Ryffel10, Siamak Bahram11, Philippe Georgel12, Jean Sibilia13, Isabelle Couillin8 and Jacques-Eric Gottenberg14, 1Laboratory of Physiopathology of Arthritises, University of Strasbourg, Illkirch-Strasbourg, France, 2Department of Biochemistry, University of Lausanne, Lausanne, Switzerland, 3Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, 4Rheumatology, Strasbourg University Hospital, Strasbourg, France, 5Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 6Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 7Molecular Immunology and Embryology, University of Orleans and National Center for Scientific Research, Orléans, France, 8Molecular Immunology and Embryology, University of Orleans and National Center for Scientific Research, Orleans, France, 9Francois Rabelais University, National institute of the health and the medical research, Tours, France, 10UMR6218, Molecular Immunology, University and CNRS, 3b rue de la Ferollerie, Orleans, France, 11Fédération of Translational Medicine of Strasbourg (FMTS), Immunorhumatology Molécular, Strasbourg, France, 12Université de Strasbourg, Laboratoire d'ImmunoGénétique Moléculaire Humaine, Strasbourg, France, 13Rheumatology, CHU Hautepierre, Strasbourg, France, 14Strasbourg University Hospital, Strasbourg, France

    Background/Purpose: Interstitial pneumonitis and lung fibrosis are frequent systemic complications of inflammatory arthritides, including systemic sclerosis (SSc), rheumatoid arthritis, or primary Sjögren’s syndrome. B lymphocytes…
  • Abstract Number: 2582 • 2013 ACR/ARHP Annual Meeting

    Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma  Cohort

    Virginia D. Steen1 and Robyn T. Domsic2, 1Department of Rheumatology, Georgetown University Medical Center, Washington, DC, 2Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Trials of therapy in  pulmonary  hypertension(PH)  have generally excluded patients with significant interstitial lung disease, but many patients with systemic sclerosis(SSc)  and  PH  have…
  • Abstract Number: 2574 • 2013 ACR/ARHP Annual Meeting

    Early Use of Prostacyclin Therapy Improves Transplant-Free Survival in Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension Plus Interstitial Lung Disease

    Elizabeth Volkmann1, Rajan Saggar2, Bryant Torres1, Lynne Yoder2, Robert Elashoff3, Rajeev Saggar4, Harsh Agrawal1, Nabeel Borazan5, Sarah Thomas1 and Daniel Furst1, 1Medicine, University of California, Los Angeles, Los Angeles, CA, 2Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 3Biomath, University of California, Los Angeles, Los Angeles, CA, 4Critical Care Medicine, St. Joseph's Hospital and Medical Center, Phoenix, AZ, 5Medicine, Rheumatology UCLA, Los Angeles, CA

    Background/Purpose: The leading causes of death in systemic sclerosis (SSc) are pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). Use of PAH therapy in…
  • Abstract Number: 2575 • 2013 ACR/ARHP Annual Meeting

    Utility Of Autoantibody Testing For Predicting Risk Of Pulmonary Arterial Hypertension: A Retrospective Analysis In Routine Autoantibody Laboratory

    Masataka Kuwana1, Yuichiro Shirai1, Hidekata Yasuoka1, Tsutomu Takeuchi1 and Kenichi Masui2, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Department of Anesthesiology, National Defense Medical College, Tokorozawa, Japan

    Background/Purpose: Pulmonary arterial hypertension (PAH) is an intractable complication of connective tissue disease (CTD). Current guidelines recommend early detection and intervention for improvement of outcomes.…
  • Abstract Number: 2580 • 2013 ACR/ARHP Annual Meeting

    Does Mycophenolate Mofetil (MMF) Have An Effect On Pulmonary Hemodynamics? Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort

    Lesley Ann Saketkoo1, Matthew R. Lammi2, Jessica K. Gordon3, Paula Lauto4 and Virginia D. Steen5, 1LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 2Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 3Rheumatology, Hospital for Special Surgery, New York, NY, 4Pulmonary and Critical Care Medicine, LSU Health Sciences Center, New Orleans, LA, 5Department of Rheumatology, Georgetown University Medical Center, Washington, DC

    Does Mycophenolate Mofetil (MMF) have an effect on Pulmonary Hemodynamics? Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) CohortBackground/Purpose: Systemic…
  • Abstract Number: 2585 • 2013 ACR/ARHP Annual Meeting

    Left Ventricular Dysfunction Reflected By Higher Serum Brain Natriuretic Peptide Accounts For Poorer Prognosis Of Pulmonary Arterial Hypertension Associated With Systemic Sclerosis

    Sumiaki Tanaka1, Yoshiyuki Arinuma1, Tatsuhiko Wada1, Tatsuo Nagai2, Jun Okada3 and Shunsei Hirohata1, 1Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, 2Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, 3Nutritional management, Kitasato Junior Collage of health and Hygienic Sciences, Minami-Uonuma, Japan

    Background/Purpose: Recentry, development of potent effective newer drugs for pulmonary arterial hypertension (PAH) have resulted in improving survival of the patients.  However, the prognosis of…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology